The effects of gp100 and tyrosinase peptide vaccinations on nevi in melanoma patients

Journal of Cutaneous Pathology
David S CassarinoPaul H Duray

Abstract

A new approach to prevent disease recurrence in high-risk melanoma patients involves immunization with gp100 and tyrosinase peptides. This is the first study to examine the effects of such treatments on nevi. We studied biopsies of 'clinically atypical' nevi from 10 patients before and after peptide vaccination. All had a cutaneous melanoma measuring at least 1.5 mm in depth, satellite metastases, or at least one positive lymph node. We performed immunohistochemical stains for CD3, CD4, CD8, MHC-I, MHC-II, CD1a, HMB-45, MART-1, tyrosinase, bcl-2, p53, and Ki-67 (mib-1). Immunohistochemistry showed no differences in staining due to vaccination in either the immunologic or melanocytic markers. However, there was a significant increase in both p53 and bcl-2 staining, and a trend toward decreased Ki-67 staining, in the nevi post-treatment. The primary goal of peptide vaccinations with gp100 and tyrosinase is to activate melanoma-specific T cells in order to prevent melanoma recurrence. Nevi were studied in order to assess the effects on benign melanocytes. No significant changes in lymphocytes, langerhans cells, expression of MHC antigens, or melanocytic markers were found. The increase in p53 and bcl-2 raises the possibility that ...Continue Reading

References

Dec 1, 1991·The American Journal of Dermatopathology·G BenzC Schmoeckel
Mar 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·A A CreaseyT C Merigan
Dec 22, 1994·Nature·A ZieglerD E Brash
Jun 1, 1993·The British Journal of Dermatology·J M McGregorD M MacDonald
Oct 31, 1997·Journal of the American Academy of Dermatology·R A ZeffJ M Grant-Kels
Oct 6, 1998·Hematology/oncology Clinics of North America·M A Weinstock
Nov 7, 1998·The Journal of Biological Chemistry·A Nalca, V M Rangnekar
Aug 24, 1999·Annals of Surgical Oncology·K M McMastersM I Ross
Dec 22, 1999·The Journal of Immunology : Official Journal of the American Association of Immunologists·M C PanelliF M Marincola
Feb 24, 2001·The American Journal of Dermatopathology·L X LiJ J Kril
Aug 16, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C M BalchJ F Thompson
May 9, 2002·Apoptosis : an International Journal on Programmed Cell Death·M H-L Ng
Oct 31, 2002·European Journal of Clinical Investigation·E Lázár-MolnárA Falus
Oct 31, 2002·Seminars in Oncology·Boris R Minev
Dec 4, 2002·Proceedings of the National Academy of Sciences of the United States of America·Drew Pardoll
Mar 6, 2003·Journal of Surgical Oncology·Kelly M McMasters, Susan M Swetter
Jun 27, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·V Bataille
Nov 25, 2003·The American Journal of Dermatopathology·Mahmoud R HusseinGary S Wood
Jan 28, 2004·Proceedings of the National Academy of Sciences of the United States of America·Matteo MarsiliFrantisek Slanina
Sep 2, 2004·Nature Medicine·Steven A RosenbergNicholas P Restifo

❮ Previous
Next ❯

Citations

Dec 6, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mariano R GabriDaniel F Alonso

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.